« Return to News | Drug Sponsors

Sanofi signs deal with Glenmark

Monday, May 16, 2011 12:59 PM

France-based Sanofi has licensed a potential treatment for Crohn's disease from India's Glenmark Pharmaceuticals, according to Pharma Times.

The drug is now called GBR500 and is a monoclonal antibody to treat Crohn’s and other chronic autoimmune disorders. It is a first-in-class antagonist of the VLA-2 (alpha2-beta1) integrin.  GBR500 has completed a phase I study in the U.S. and the treatment has been well tolerated.

Glenmark will receive an upfront fee of $50 million; $25 million will be paid at the closing of the deal. The remainder is contingent upon Sanofi’s "positive assessment of certain data.” This data will be provided by Glenmark.

Glenmark could also receive success-based development, regulatory and commercial milestone payments worth over $600 million, plus royalties, says Pharma Times. Sanofi will get exclusive marketing rights in North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay, and co-marketing or co-promotion rights in Brazil, Russia, Australia and New Zealand. Glenmark will retain rights in India and the rest of the world.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.